Scientific Programme
Bradykinin Symposium
Thursday, 15 September 2022
12:00-12:45
Lunch
12:45-13:00
Welcome
Marcus Maurer, Markus Magerl (Germany)
Session I: Bradykinin Basics
13:00-13:50
Kinin Formation, turnover and signaling
Thomas Renné (Germany)
13:50-14:15
The kallikrein-kinin system and its neighbors
Michael Bader (Germany)
14:15-14:45
Coffee Break
Session II: News in Bradykinin biology
14:45-15:10
The role of arachidonic acid metabolites for bradykinin-induced dermal extravasation. Studies in mice and humans.
Georg Kojda (Germany)
15:10-15:35
Hereditary Angioedema with a Mutation in the Plasminogen
Allen Kaplan (USA)
The pathophysiology of BK in COVID
Allen Kaplan (USA)
15:35-16:00
The endothelial response to Bradykinin and other vasoactive substances
Maria Bova (Italy)
16:00-16:30
Coffee Break
Session III: Short oral presentations
16:30-16:40
Characteristics of pediatric subjects with C1-HAE deficiency in the ITACA cohort
Riccardo Senter (Italy)
16:40-16:50
A novel pathogenetic factor of laryngeal attack in hereditary angioedema? Involvement of Protease Activated Receptor 1
László Cervenak (Hungary)
16:50-17:00
Bradykinin receptor-1 on monocytes and granulocytes increase rapidly after LPS
Erik Nielsen (Norway)
17:00-17:10
Development of Dutch National Dynamic Flowchart and Registry for Angioedema
Marloes W. Heijstek (Netherlands)
17:10-17:20
Comorbidities in Angioedema due to C1-inhibitor deficiency: an Italian survey
Riccardo Senter (Italy)
17:20-17:25
Closing Remarks
17:25-18:10
Walk to Dinner Location
18:10-18:45
Reception
20:15-20:45
Quiz
20:45-23:00
Scientific Dinner
Friday, 16 September 2022
8:00-8:15
Coffee and Welcome
8:15-8:20
Summary day 1
Marcus Maurer, Markus Magerl (Germany)
Session IV: Bradykinin and angioedema
8:20-8:35
Classification of angioedema: The 2022 approach
Avner Reshef (Israel)
8:35-8:50
How to measure Bradykinin and other kinins in angioedema patients
Björn Burckhardt (USA)
8:50-9:05
Clinical and Laboratory evaluation of Bradykinin mediated angioedema
Henriette Farkas (Hungary)
9:05-9:20
Genetics and its use for diagnostics in angioedema
Anastasios Germenis (Greece)
9:20-9:35
AAE: The neglected little brother
Anete S Grumach (Brazil)
9:35-10:05
Coffee Break
Session V: Short Oral Presentations
10:05-10:15
Pharmacology of KVD824, an Investigational Drug for Prophylaxis of HAE
Vesna Grivcheva-Panovska (Macedonia)
10:15-10:25
Pharmacological characterization of a novel oral FXIIa inhibitor KV998086
Allen Clermont (USA)
10:25-10:35
Pregnancy in women with Hereditary Angioedema due to C1-inhibitor deficiency: Results from the ITACA cohort study on outcome of mothers and children with in utero exposure to plasma-derived C1-inhibitor
Paola Triggianese (Italy)
10:35-10:45
Sebetralstat, Investigational Oral On-Demand Treatment for HAE: KONFIDENT Trial Design
Emel Aygören-Pürsün (Germany)
10:45-10:55
Development of PHA121 for On-Demand and Prophylactic Treatment of HAE
Giorgio Giannattasio (Switzerland)
10:55-11:05
In vivo CRISPR/Cas9 editing of KLKB1 in Patients with HAE
Hilary Longhurst (New Zealand)
11:05-11:25
Coffee Break
Session VI: Hereditary angioedema
11:25-11:40
Comorbidities in HAE
Linda Sundler Björkman (Sweden)
11:40-11:55
Mortality in HAE
Fernanda Minafra (Brazil)
11:55-12:10
On demand treatment from the patients’ perspective in real life
Semra Demir (Turkey)
12:10-12:25
Outcome measures of acute therapy for hereditary angioedema
Lauré Fijen (Netherlands)
12:25-12:45
Modern prophylaxis in real life
Laurence Bouillet (France)
12:45-13:35
Lunch
Session VII: Hereditary angioedema
13:35-13:55
Update on HAE with normal C1-INH: Mutations and clinical features
Konrad Bork (Germany)
13:55-14:15
Bradykinin formation in HAE with normal C1-INH
Allen Kaplan (USA)
14:15-14:45
Pathomechanism in HAE with normal C1-INH beyond Bradykinin – Round table discussion
Konrad Bork (Germany), Thomas Renne (Germany),
Allen Kaplan (USA)
14:45-15:25
Poster Session
Session VIII: HAE worldwide
15:25-15:45
HAE in India: A country with 30000 patients?
Ankur Jindal (India)
15:45-16:05
Prophylaxis as standard treatment? What can we learn from Canada?
Stephen Betschel (Canada)
16:05-16:25
All for the patient: HAEi & ACARE
Henrik Boysen (Denmark)
16:25-16:45
Speculating about future treatments
Danny Cohn (Netherlands)
16:45-17:00
Conclusions: What did we hear? What take we home?
Markus Magerl (Germany)
17:00-17:15
Closing remarks
Marcus Maurer, Markus Magerl (Germany)
as of 13 September 2022
